Editas Medicine

EDIT67

Penny Stock

$3.91arrow_drop_up0.77%$0.03

Penny Stock

EDIT67

$3.91

arrow_drop_up0.77%$0.03

Penny Stock

Performance History

Key Stats
Open	$4.01
Prev. Close	$3.86
EPS	-2.33
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$318.35M
PE Ratio	-

	LOW	HIGH
Day Range	3.86	4.12
52 Week Range	3.40	11.69

Ratios







EPS	-2.33

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Editas Medicine (EDIT)

Editas Medicine Inc (EDIT) is a leading biotechnology company focused on developing and commercializing genome editing technologies. With its proprietary CRISPR-based platform, Editas is at the forefront of a revolutionary field that has the potential to transform the treatment of genetic diseases. The company's mission is to translate its genetic expertise into innovative therapies that have a meaningful impact on patients' lives.

One of Editas Medicine's key strengths is its deep pipeline of programs targeting a wide range of genetic diseases. The company has a diverse portfolio of therapies in development, including treatments for rare inherited retinal diseases, blood disorders, and neurological conditions. With its cutting-edge technology and extensive scientific expertise, Editas is well-positioned to address the unmet needs of patients suffering from these devastating diseases.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Gilmore O'Neill
Headquarters: Cambridge
Employees: 226
Exchange: NASDAQ

Keep an eye on Editas Medicine

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Editas Medicine 's (EDIT) price per share?

The current price per share for Editas Medicine (EDIT) is $3.91. The stock has seen a price change of $0.03 recently, indicating a 0.77% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Editas Medicine (EDIT)?

For Editas Medicine (EDIT), the 52-week high is $11.69, which is 198.98% from the current price. The 52-week low is $3.4, the current price is 15% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Editas Medicine (EDIT) a growth stock?

Editas Medicine (EDIT) has shown an average price growth of 0.41% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Editas Medicine as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Editas Medicine (EDIT) stock price performance year to date (YTD)?

As of the latest data, Editas Medicine (EDIT) has a year-to-date price change of -60.82%. Over the past month, the stock has experienced a price change of -4.63%. Over the last three months, the change has been -22.42%. Over the past six months, the figure is -49.35%. Looking at a longer horizon, the five-year price change stands at -84.54%.

help

Is Editas Medicine (EDIT) a profitable company?

Editas Medicine (EDIT) has a net income of -$153.22M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 92.24% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -14.02K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $78.12M, although specific revenue growth data is currently not available. The gross profit is $72.06M. Operating income is noted at -$169.18M. Furthermore, the EBITDA is -$207.21M.

help

What is the market capitalization of Editas Medicine (EDIT)?

Editas Medicine (EDIT) has a market capitalization of $318.36M. The average daily trading volume is 1.96M, indicating the stock's liquidity and investor engagement.

News

Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology

Editas Medicine to Participate in Upcoming Investor Conferences

6/17/2024

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

CALENDAR OF EVENTS

CLINICAL STUDY

6/14/2024

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

CLINICAL STUDY

6/14/2024

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About Editas Medicine (EDIT)

Keep an eye on Editas Medicine

Frequently Asked Questions

What is Editas Medicine 's (EDIT) price per share?

What is the 52-week high and low for Editas Medicine (EDIT)?

Is Editas Medicine (EDIT) a growth stock?

What is Editas Medicine (EDIT) stock price performance year to date (YTD)?

Is Editas Medicine (EDIT) a profitable company?

What is the market capitalization of Editas Medicine (EDIT)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level